Roth Remains Positive on Ligand (LGND) Following Kyprolis Q4 Sales Data, sNDA Filing (AMGN)
Tweet Send to a Friend
Roth Capital affirms Ligand Pharma (Nasdaq: LGND) at Buy with a price target of $116 following Kyprolis Q4 revenue data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
